Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCX-201 + monomethyl auristatin E
- Development stage
- Preclinical
- Lead developer
- Tacalyx
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**TCX-201 + monomethyl auristatin E** is a preclinical antibody-drug conjugate developed by Tacalyx for solid tumors. It consists of the fully humanized TACA-targeting antibody TCX-201 conjugated through a cleavable linker to the cytotoxic microtubule-disrupting payload monomethyl auristatin E, with a reported drug-to-antibody ratio of 4. The precise tumor-associated carbohydrate antigen target has not been publicly disclosed. In preclinical pancreatic and colorectal cancer models, the MMAE conjugate showed potent target-dependent cell killing and antitumor activity following intravenous dosing. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/86/7_Supplement/5631/780526/Abstract-5631-TCX-201-a-novel-ADC-targeting-a))
- Other names
- TCX-201 MMAETCX201 MMAETCX 201 MMAE
02
Targets
MicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TCX-201 + monomethyl auristatin E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCX-201 + monomethyl auristatin E.